Patents by Inventor Remi J. Creusot

Remi J. Creusot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
    Patent number: 10238741
    Abstract: The invention relates to constructs, cells and methods for modulating the immune system that optimize presentation of CD4 and CD8 epitopes to antigen-presenting cells and transfection into cells. Epitopes to either self antigens or non-self antigens can be used to optimize either a tolerance or immunogenicity to those epitopes, respectively. Certain new constructs encode one or more dominant, disease-driving epitopes (CD4) targeted for MHCII processing within the endosomes of a cell and one or more epitopes (CD8) targeted for MHCI processing within the cytosol of the cell, to produce the maximum antigen/epitope presentation in the immune system, and further include an MHCII activator sequence. Alternatively, the new constructs encode CD4 and CD8 epitopes operably linked to a secretion signal.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: March 26, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Remi J. Creusot
  • Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
    Publication number: 20170283810
    Abstract: The invention relates to constructs, cells and methods for modulating the immune system that optimize presentation of CD4 and CD8 epitopes to antigen-presenting cells and transfection into cells. Epitopes to either self antigens or non-self antigens can be used to optimize either a tolerance or immunogenicity to those epitopes, respectively. Certain new constructs encode one or more dominant, disease-driving epitopes (CD4) targeted for MHCII processing within the endosomes of a cell and one or more epitopes (CD8) targeted for MHCI processing within the cytosol of the cell, to produce the maximum antigen/epitope presentation in the immune system, and further include an MHCII activator sequence. Alternatively, the new constructs encode CD4 and CD8 epitopes operably linked to a secretion signal.
    Type: Application
    Filed: April 10, 2017
    Publication date: October 5, 2017
    Applicant: The Trustees of Columbia University in the City of New York
    Inventor: Remi J. Creusot